Effects of Almond Versus Pistachio on Weight Loss

N/ACompletedNCT03120455

Novindiet Clinic120 enrolled

Overview

The purpose of the current study is comparing the effect of almond and pistachio, as the two common types of nuts, consumption on healthy obese and overweight female who following a hypocaloric diet for 12 weeks. The secondary aim of the current study is to evaluate of these two type of nuts on other cardiometabolic risk factors.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

120

Conditions

Obesity Overweight

Interventions

Almond GroupBEHAVIORAL

Obese or overweight female adults will be randomly allocated to have almond as afternoon snacks, while they have a hypoenergetic diet.

Pistachio GroupBEHAVIORAL

Obese or overweight female adults will be randomly allocated to have Pistachio as afternoon snacks, while they have a hypoenergetic diet.

Nut free groupBEHAVIORAL

Obese or overweight female adults will be asked to avoid nuts, seeds and nut products, while they have a hypoenergetic diet.

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Must be female * Must be 18-45 years of age. * Must have Body mass index (BMI) between 27-35 kg/ m². * Must be able to have moderate exercise. * Must be interested to have weight loss. Exclusion Criteria: * Have allergy to nuts * Participating in a research project involving weight loss or physical activity in the previous six months. * Pregnancy or lactation during the previous 6 months, or planned pregnancy in the next six months. * Taking medication that could affect metabolism or change body weight. * Report heart problems, chest pain, and cancer within the last five years. * Smoking * Menopause * Diagnosis of any chronic disease such as fatty liver, cancer, chemo/radio therapy, heart disease, immune compromised conditions, abnormal thyroid hormone level.

Locations (1)

NovinDiet Clinic

Tehran, Iran

Outcomes

Primary Outcomes

Weight

Body weight was taken to the nearest 0.1 kg using a digital calibrated scale (Omron Health Care, Hoofddorp, Netherland), whilst subjects wore light clothing and no shoes.

Time frame: 12 Weeks

Secondary Outcomes

Waist circumference

Waist circumference (WC) was measured with a rigid measuring tape and recorded to the nearest 0.5 cm. WC was measured at the smallest horizontal circumference between the ribs and iliac crest (the natural waist), or, in case of an indeterminable waist narrowing, halfway between the lower rib and the iliac crest.

Time frame: 12 Weeks

fasting blood glucose

Fasting plasma glucose (FPG) were measured using the enzymatic colorimetric method.

Time frame: 12 Weeks

HbA1c

Glycated hamoglobin (HbA1c) was measured by a colorimetric method after an initial separation by ion exchange chromatography (Biosystem, Barcelona, Spain).

Time frame: 12 Weeks

HOMA-IR

Insulin resistance was evaluated by homeostasis model assessment of insulin resistance (HOMA-IR), which was calculated by using the following formula HOMA-IR = \[fasting insulin (mU/l) × FPG (mmol/l)\]/22.5

Time frame: 12 Weeks

lipid profiles

Biochemical analysis of the serum total cholesterol (TC), triglyceride (TG), and high-density lipoprotein (HDL) cholesterol was carried out on a Selectra E auto analyzer (Vita Laboratory, Netherlands) following standard procedures of the Pars Azmoon diagnostic kits (Iran). The LDL cholesterol was calculated using the Friedewald formula. LDL cholesterol = TC - HDL cholesterol + (TG ÷ 2.2)

Time frame: 12 Weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.